Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Prime Msk Shot is under clinical development by Thomas Advanced Medical and currently in Phase II for Unspecified Neurologic Disorders.

PF-07054894 is under development for the treatment of inflammatory bowel disease and ulcerative colitis. It is administered through oral route. The drug candidate is a new molecular entity. It acts by ...

APG-157 is under clinical development by Aveta Biomics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

LXE-408 is under clinical development by Novartis and currently in Phase I for Chagas Disease (American Trypanosomiasis).

NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate ...

Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome.

ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Melanoma.

TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Endometrial Cancer.